Democrat lawmakers launch major investigation into pharmaceutical pricing

15 January 2019
ussenate-big

A powerful committee of the freshly inaugurated Democrat-led US House of Representatives has launched a far-ranging investigation into the drug pricing practices of the US pharmaceutical industry.

Chairman Elijah Cummings has sent letters to 12 drug companies requesting evidence related to their internal processes, including “information and communications on price increases, investments in research and development, and corporate strategies to preserve market share and pricing power.”

A number of these drugmakers saw their stock prices fall in the wake of the announcement from the Committee on Oversight and Reform.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical